title: Anastomotic dehiscence during treatment with bevacizumab 5 years after colo-anal anastomosis with proposition for management without stopping chemotherapy.
authors.forename: C
authors.initials: C
authors.lastname: Eveno
authors.forename: P
authors.initials: P
authors.lastname: Soyer
authors.forename: L
authors.initials: L
authors.lastname: Teixeira
authors.forename: L
authors.initials: L
authors.lastname: Staudacher
authors.forename: M
authors.initials: M
authors.lastname: Pocard
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000601:surgery*; D000368:Aged; D001003:Anal Canal / Q000601:surgery*; D000714:Anastomosis, Surgical; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068258:Bevacizumab; D003106:Colon / Q000601:surgery*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000601:surgery*; D013529:Surgical Wound Dehiscence / Q000139:chemically induced*; D013997:Time Factors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab